Characteristics of 1-y survivors by type of first primary NHL diagnosed from age 20 to 84 y, 17 SEER registry areas, 2000 to 2014
| Characteristic . | CLL/SLL, % (n = 42 119) . | DLBCL, % (n = 41 416) . | FL, % (n = 29 508) . | MZL, % (n = 14 001) . |
|---|---|---|---|---|
| Age at first primary NHL, y | ||||
| <60 | 29.5 | 46.4 | 47.8 | 40.1 |
| ≥60 | 70.5 | 53.6 | 52.2 | 59.9 |
| Mean | 65.9 | 59.7 | 60.4 | 62.5 |
| Mean follow-up time, y | 4.5 | 4.6 | 5.2 | 4.8 |
| Sex | ||||
| Male | 60.5 | 54.9 | 49.9 | 45.4 |
| Female | 39.5 | 45.1 | 50.1 | 54.6 |
| Race | ||||
| White/unknown | 90.1 | 84.0 | 90.4 | 83.9 |
| African American | 7.4 | 7.7 | 4.7 | 8.1 |
| Other | 2.5 | 8.3 | 4.9 | 8.0 |
| Year of first primary NHL diagnosis | ||||
| 2000-2004 | 34.0 | 33.2 | 34.6 | 30.5 |
| 2005-2009 | 36.8 | 36.2 | 37.7 | 37.8 |
| 2010-2014 | 29.3 | 30.6 | 27.7 | 31.7 |
| First course of NHL treatment | ||||
| CT and RT | 0.6 | 24.4 | 7.5 | 4.6 |
| CT, no known RT | 21.1 | 61.8 | 49.2 | 27.9 |
| RT, no known CT | 0.7 | 2.0 | 9.3 | 20.1 |
| No known CT or RT | 77.6 | 11.8 | 34.0 | 47.4 |
| Stage at first primary NHL* | ||||
| Early | 71.5 | 51.6 | 42.5 | 51.3 |
| Advanced | 28.5 | 43.1 | 50.2 | 32.8 |
| Unknown | — | 5.3 | 7.3 | 15.9 |
| Primary site (NHL) | ||||
| Nodal | — | 64.3 | — | 40.0 |
| Extranodal, gastric | — | 4.6 | — | 20.3 |
| Extranodal, nongastric | — | 31.0 | — | 39.7 |
| HIV/AIDS status at NHL diagnosis | ||||
| Reported HIV/AIDS | 0.1 | 3.6 | 0.5 | 0.7 |
| No known HIV/AIDS | 99.9 | 96.4 | 99.5 | 99.3 |
| Characteristic . | CLL/SLL, % (n = 42 119) . | DLBCL, % (n = 41 416) . | FL, % (n = 29 508) . | MZL, % (n = 14 001) . |
|---|---|---|---|---|
| Age at first primary NHL, y | ||||
| <60 | 29.5 | 46.4 | 47.8 | 40.1 |
| ≥60 | 70.5 | 53.6 | 52.2 | 59.9 |
| Mean | 65.9 | 59.7 | 60.4 | 62.5 |
| Mean follow-up time, y | 4.5 | 4.6 | 5.2 | 4.8 |
| Sex | ||||
| Male | 60.5 | 54.9 | 49.9 | 45.4 |
| Female | 39.5 | 45.1 | 50.1 | 54.6 |
| Race | ||||
| White/unknown | 90.1 | 84.0 | 90.4 | 83.9 |
| African American | 7.4 | 7.7 | 4.7 | 8.1 |
| Other | 2.5 | 8.3 | 4.9 | 8.0 |
| Year of first primary NHL diagnosis | ||||
| 2000-2004 | 34.0 | 33.2 | 34.6 | 30.5 |
| 2005-2009 | 36.8 | 36.2 | 37.7 | 37.8 |
| 2010-2014 | 29.3 | 30.6 | 27.7 | 31.7 |
| First course of NHL treatment | ||||
| CT and RT | 0.6 | 24.4 | 7.5 | 4.6 |
| CT, no known RT | 21.1 | 61.8 | 49.2 | 27.9 |
| RT, no known CT | 0.7 | 2.0 | 9.3 | 20.1 |
| No known CT or RT | 77.6 | 11.8 | 34.0 | 47.4 |
| Stage at first primary NHL* | ||||
| Early | 71.5 | 51.6 | 42.5 | 51.3 |
| Advanced | 28.5 | 43.1 | 50.2 | 32.8 |
| Unknown | — | 5.3 | 7.3 | 15.9 |
| Primary site (NHL) | ||||
| Nodal | — | 64.3 | — | 40.0 |
| Extranodal, gastric | — | 4.6 | — | 20.3 |
| Extranodal, nongastric | — | 31.0 | — | 39.7 |
| HIV/AIDS status at NHL diagnosis | ||||
| Reported HIV/AIDS | 0.1 | 3.6 | 0.5 | 0.7 |
| No known HIV/AIDS | 99.9 | 96.4 | 99.5 | 99.3 |
CT, chemotherapy; RT, radiotherapy.
Early stage: Ann Arbor stages I and II for DLBCL, FL, and MZL and no known initial treatment of CLL; advanced stage: Ann Arbor stages III and IV for DLBCL, FL, and MZL and any initial treatment of CLL.